TG-1000

DRUG2 trials

Sponsors

TaiGen Biotechnology Co., Ltd.

Conditions

Healthy Chinese VolunteersInfluenza Virus Infection

Phase 1

To Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of TG-1000 in Healthy Volunteers, and the Food Effect on Pharmacokinetics of Single Oral Dose of TG-1000 in Healthy Volunteers.

CompletedNCT04495322

TaiGen Biotechnology Co., Ltd.Healthy Chinese Volunteers

Start: 2020-07-17End: 2020-12-30Updated: 2021-01-07

Phase 2

To Evaluate the Efficacy and Safety of TG-1000 Compared With Placebo in Adult Patients With Acute Uncomplicated Influenza Virus Infection

CompletedNCT04706468

TaiGen Biotechnology Co., Ltd.Influenza Virus Infection

Start: 2020-12-15End: 2022-02-15Updated: 2022-03-09